Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Rationale</h3><p>Among its many biological roles, fibroblast growth factor 2 (FGF2) protects the heart from dysfunction and damage associated with an ischemic attack. Our laboratory demonstrated that its protection against myocardial dysfunction occurs by the low molecular weight (LMW) isoform of FGF2, while the high molecular weight (HMW) isoforms are associated with a worsening in post-ischemic recovery of cardiac function. LMW FGF2-mediated cardioprotection is facilitated by activation of multiple kinases, including PKCalpha, PKCepsilon, and ERK, and inhibition of p38 and JNK.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objective</h3><p>Yet, the substrates of those kinases associated with LMW FGF2-induced cardioprotection against myocardial dysfunction remain to be elucidated.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods and results</h3><p>To identify substrates in LMW FGF2 improvement of post-ischemic cardiac function, mouse hearts expressing only LMW FGF2 were subjected to ischemia-reperfusion (I/R) injury and analyzed by a mass spectrometry (MS)-based quantitative phosphoproteomic strategy. MS analysis identified 50 phosphorylation sites from 7 sarcoendoplasmic reticulum (SR) proteins that were significantly altered in I/R-treated hearts only expressing LMW FGF2 compared to those hearts lacking FGF2. One of those phosphorylated SR proteins identified was phospholamban (PLB), which exhibited rapid, increased phosphorylation at Threonine-17 (Thr17) after I/R in hearts expressing only LMW FGF2; this was further validated using Single Reaction Monitoring-based MS workflow. To demonstrate a mechanistic role of phospho-Thr17 PLB in LMW FGF2-mediated cardioprotection, hearts only expressing LMW FGF2 and those expressing only LMW FGF2 with a mutant PLB lacking phosphorylatable Thr17 (Thr17Ala PLB) were subjected to I/R. Hearts only expressing LMW FGF2 showed significantly improved recovery of cardiac function following I/R (<em>p</em> < 0.05), and this functional improvement was significantly abrogated in hearts expressing LMW FGF2 and Thr17Ala PLB (<em>p</em> < 0.05).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>The findings indicate that LMW FGF2 modulates intracellular calcium handling/cycling via regulatory changes in SR proteins essential for recovery from I/R injury, and thereby protects the heart from post-ischemic cardiac dysfunction.</p>

Dual Site Phospholamban Phosphorylation and Its Physiological Relevance in the Heart.

Functional Consequence of Protein Kinase A-dependent Phosphorylation of the Cardiac Ryanodine Receptor: Sensitization of Store Overload-Induced Ca2+ Release.

Frequency-encoding Thr17 Phospholamban Phosphorylation Is Independent of Ser16 Phosphorylation in Cardiac Myocytes

14-3-3 binding creates a memory of kinase action by stabilizing the modified state of phospholamban

Threonine-17 phosphorylation of phospholamban: a key determinant of frequency-dependent increase of cardiac contractility.

Phosphorylation-induced structural change in phospholamban and its mutants, detected by intrinsic fluorescence.

Direct spectroscopic detection of molecular dynamics and interactions of the calcium pump and phospholamban.

Protein docking and steered molecular dynamics suggest alternative phospholamban-binding sites on the SERCA calcium transporter

The Critical Role of Phospholamban in Cardiac Function

Understanding the Molecular Mechanism of PLCε Regulation and G Protein‐Mediated Activation

Phospholamban phosphorylation increases the passive calcium leak from cardiac sarcoplasmic reticulum

Phosphoproteomic analysis identifies phospho-Threonine-17 site of phospholamban important in low molecular weight isoform of fibroblast growth factor 2-induced protection against post-ischemic cardiac dysfunction

Molecular noise filtering in the β-adrenergic signaling network by phospholamban pentamers

ZBTB20 Regulates SERCA2a Activity and Myocardial Contractility Through Phospholamban

Ser-2030, but Not Ser-2808, is the Major Phosphorylation Site in Cardiac Ryanodine Receptors Responding to Protein Kinase A Activation Upon Beta-Adrenergic Stimulation in Normal and Failing Hearts.

Structures of PKA–phospholamban complexes reveal a mechanism of familial dilated cardiomyopathy

Phospholemman Modulates The Gating Of Cardiac L-Type Calcium Channels

Intracellular β1-Adrenergic Receptors and Organic Cation Transporter 3 Mediate Phospholamban Phosphorylation to Enhance Cardiac Contractility

Phospholamban Knockout Breaks Arrhythmogenic Ca2+ Waves and Suppresses Catecholaminergic Polymorphic Ventricular Tachycardia in Mice

Anchored PKA and regulation of calcium handling in cardiomyocytes

Intracellular Β 1 -Adrenergic Receptors and Organic Cation Transporter 3 Mediate Phospholamban Phosphorylation to Enhance Cardiac Contractility